Kanako Kikuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kanako Kikuchi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
K. Tamaki
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
3 shared publicationsT. Hoashi
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
2 shared publications- Kazumasa Wakamatsu
Institute for Melanin Chemistry, Fujita Health University
1 shared publication Kunihiko Tamaki
1 shared publicationM. Kubo
Department of Dermatology, Faculty of Medicine, University of Tokyo, Japan
1 shared publication- Mayumi Komine
Department of Dermatology Jichi Medical University Shimotsuke City Tochigi Japan
1 shared publication
Latest Publications
- 6 October 2008
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 33 (6) , 750-753
Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy
Background. Ultraviolet (UV) B radiation from sunlight can result in tanning or burning of the skin. Narrowband UVB (NB‐UVB), a relatively new light source that is not yet widely available, is effective for treating generalized psoriasis without the use of psoralens. Aims. The melanin‐related metabolite 5‐S‐cysteinyldopa (5‐S‐CD), which reflects pheomelanin production, has been used as a biological marker of melanoma progression, but there are no studies available on therapeutic UVB effects on serum 5‐S‐CD of human subjects. In the present study, we measured the time course of changes in serum levels of 5‐S‐CD in patients with psoriasis undergoing NB‐UVB phototherapy. Methods. In total, 11 Japanese patients with generalized psoriasis vulgaris received NB‐UVB treatment five times per week, at an initial dose of 0.1 J/cm2. The dose was increased by 10–20% per treatment for > 20 treatments. Serum samples were taken before and 3, 7, 10, 14 and 28 days after phototherapy. Results. After 4 weeks of NB‐UVB treatment, 9 of 11 patients were in remission, confirming the effectiveness of NB‐UVB for treating Japanese patients with psoriasis. Two patients withdrew before day 28 because of other complications. Mean level of 5‐S‐CD in serum was significantly increased on day 7, 10 14 and 28 compared with the level before phototherapy and it peaked on day 10. Conclusions. Serum 5‐S‐CD levels were significantly increased by therapeutic UVB exposure. Sustained levels of 5‐S‐CD in serum appear to reflect the degree of skin injury during NB‐UVB phototherapy.
- 6 October 2008
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 33 (6) , 750-753
Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy
Background. Ultraviolet (UV) B radiation from sunlight can result in tanning or burning of the skin. Narrowband UVB (NB‐UVB), a relatively new light source that is not yet widely available, is effective for treating generalized psoriasis without the use of psoralens. Aims. The melanin‐related metabolite 5‐S‐cysteinyldopa (5‐S‐CD), which reflects pheomelanin production, has been used as a biological marker of melanoma progression, but there are no studies available on therapeutic UVB effects on serum 5‐S‐CD of human subjects. In the present study, we measured the time course of changes in serum levels of 5‐S‐CD in patients with psoriasis undergoing NB‐UVB phototherapy. Methods. In total, 11 Japanese patients with generalized psoriasis vulgaris received NB‐UVB treatment five times per week, at an initial dose of 0.1 J/cm2. The dose was increased by 10–20% per treatment for > 20 treatments. Serum samples were taken before and 3, 7, 10, 14 and 28 days after phototherapy. Results. After 4 weeks of NB‐UVB treatment, 9 of 11 patients were in remission, confirming the effectiveness of NB‐UVB for treating Japanese patients with psoriasis. Two patients withdrew before day 28 because of other complications. Mean level of 5‐S‐CD in serum was significantly increased on day 7, 10 14 and 28 compared with the level before phototherapy and it peaked on day 10. Conclusions. Serum 5‐S‐CD levels were significantly increased by therapeutic UVB exposure. Sustained levels of 5‐S‐CD in serum appear to reflect the degree of skin injury during NB‐UVB phototherapy.
- 14 March 2006
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 31 (3) , 381-383
Pseudoscleroderma associated with cancer
In the period 1994–2002, we saw 71 patients with sclerotic skin changes; 66 were diagnosed with systemic sclerosis (SSc) while five (7%) were diagnosed with pseudoscleroderma associated with various malignancies. The mean duration of disease in these five patients was significantly shorter than that of patients with SSc. The incidence of positive antinuclear antibodies, Raynaud's phenomenon or oesophageal involvement in patients with pseudoscleroderma was significantly lower than that in patients with SSc. The distributions of skin sclerosis varied in each case. Serum basic fibroblast growth factor (bFGF) levels in the five patients with pseudoscleroderma were very elevated compared with levels in controls. Elevated expression of bFGF was detected on fibroblasts of affected skin and in one lung‐cancer tissue sample obtained by excision.
- 14 March 2006
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 31 (3) , 381-383
Pseudoscleroderma associated with cancer
In the period 1994–2002, we saw 71 patients with sclerotic skin changes; 66 were diagnosed with systemic sclerosis (SSc) while five (7%) were diagnosed with pseudoscleroderma associated with various malignancies. The mean duration of disease in these five patients was significantly shorter than that of patients with SSc. The incidence of positive antinuclear antibodies, Raynaud's phenomenon or oesophageal involvement in patients with pseudoscleroderma was significantly lower than that in patients with SSc. The distributions of skin sclerosis varied in each case. Serum basic fibroblast growth factor (bFGF) levels in the five patients with pseudoscleroderma were very elevated compared with levels in controls. Elevated expression of bFGF was detected on fibroblasts of affected skin and in one lung‐cancer tissue sample obtained by excision.
- 1 July 2005
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 53 (1) , 57-61
Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa
- 1 July 2005
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 53 (1) , 57-61
Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa
- 1 June 2002
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 27 (4) , 301-305
Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis
Summary Matrix metalloproteinase‐9 (MMP‐9) and its inhibitor, tissue inhibitors of metalloproteinases‐1 (TIMP‐1) are involved in tissue inflammation and fibrotic processes. We previously reported an elevated serum TIMP‐1 level in patients with systemic sclerosis (SSc). We measured serum TIMP‐1 and active MMP‐9 levels in 62 patients with SSc, 10 patients with rheumatoid arthritis (RA) and 15 normal controls using a modified enzyme‐linked immunosorbent assay. The active MMP‐9 level in the serum of the patients with RA or SSc was not significantly different from that of controls. Serum MMP‐9 activity in patients with diffuse cutaneous SSc was significantly decreased compared with that of limited cutaneous SSc or normal controls. The MMP‐9 activity and modified‐Rodnan total skin thickness score in patients with SSc were negatively correlated. Serum MMP‐9 activity and TIMP‐1 level in patients with SSc were not correlated. Serum MMP‐9 activity might be a useful indicator of disease activity, especially skin severity, in SSc patients.
- 1 June 2002
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 27 (4) , 301-305
Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis
Summary Matrix metalloproteinase‐9 (MMP‐9) and its inhibitor, tissue inhibitors of metalloproteinases‐1 (TIMP‐1) are involved in tissue inflammation and fibrotic processes. We previously reported an elevated serum TIMP‐1 level in patients with systemic sclerosis (SSc). We measured serum TIMP‐1 and active MMP‐9 levels in 62 patients with SSc, 10 patients with rheumatoid arthritis (RA) and 15 normal controls using a modified enzyme‐linked immunosorbent assay. The active MMP‐9 level in the serum of the patients with RA or SSc was not significantly different from that of controls. Serum MMP‐9 activity in patients with diffuse cutaneous SSc was significantly decreased compared with that of limited cutaneous SSc or normal controls. The MMP‐9 activity and modified‐Rodnan total skin thickness score in patients with SSc were negatively correlated. Serum MMP‐9 activity and TIMP‐1 level in patients with SSc were not correlated. Serum MMP‐9 activity might be a useful indicator of disease activity, especially skin severity, in SSc patients.